Mostrar el registro sencillo del ítem
dc.contributor.author
Dolfi, Sonia C.
dc.contributor.author
Jager, Adriana Valeria
dc.contributor.author
Medina, Daniel J.
dc.contributor.author
Haffty, Bruce G.
dc.contributor.author
Yang, Jin Ming
dc.contributor.author
Hirshfield, Kim M.
dc.date.available
2018-01-12T19:41:50Z
dc.date.issued
2014-08
dc.identifier.citation
Dolfi, Sonia C.; Jager, Adriana Valeria; Medina, Daniel J.; Haffty, Bruce G.; Yang, Jin Ming; et al.; Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugs; Elsevier Ireland; Cancer Letters; 350; 8-2014; 52-60
dc.identifier.issn
0304-3835
dc.identifier.uri
http://hdl.handle.net/11336/33148
dc.description.abstract
The human homologue of mouse double minute 2 (MDM2) is overexpressed in tumors and contributes to tumorigenesis through inhibition of p53 activity. We investigated the effect of the anti-estrogen fulvestrant on MDM2 expression and sensitivity of estrogen receptor positive human breast cancer cell lines to chemotherapeutics. Fulvestrant down-regulated MDM2 through increased protein turnover. Fulvestrant blocked estrogen-dependent up-regulation of MDM2 and decreased basal expression of MDM2 in the absence of estradiol. As combinations of fulvestrant with doxorubicin, etoposide or paclitaxel were synergistic, altering cell cycle distribution and increasing cell death, this provides rationale for testing combinatorial chemotherapy with fulvestrant as a novel therapeutic strategy for patients with advanced breast cancer.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Elsevier Ireland
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
Fulvestrant
dc.subject
Mdm2
dc.subject
Chemotherapy
dc.subject
Estrogen Receptor
dc.subject
Breast Cancer
dc.subject.classification
Salud Ocupacional
dc.subject.classification
Ciencias de la Salud
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugs
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2018-01-12T16:16:37Z
dc.journal.volume
350
dc.journal.pagination
52-60
dc.journal.pais
Irlanda
dc.journal.ciudad
Shannon
dc.description.fil
Fil: Dolfi, Sonia C.. Rutgers Cancer Institute of New Jersey; Estados Unidos
dc.description.fil
Fil: Jager, Adriana Valeria. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; Argentina
dc.description.fil
Fil: Medina, Daniel J.. Rutgers Cancer Institute of New Jersey; Estados Unidos
dc.description.fil
Fil: Haffty, Bruce G.. Rutgers Cancer Institute of New Jersey; Estados Unidos
dc.description.fil
Fil: Yang, Jin Ming. State University of Pennsylvania; Estados Unidos
dc.description.fil
Fil: Hirshfield, Kim M.. Rutgers Cancer Institute of New Jersey; Estados Unidos
dc.journal.title
Cancer Letters
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/http://www.sciencedirect.com/science/article/pii/S0304383514002158
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.canlet.2014.04.009
Archivos asociados